Phase 2b, Open Label, Multisite, Randomized Crossover Study of DPP Versus 2PR
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Harriet Nuwagaba-Biribonwoha, MD
ICAP at Columbia University
Study Chair - Lisa Haddad, MD
Population Council
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Eswatini Prevention Center Crs
Mbabane, Eswatini
- Mu-Jhu Research Collaboration (mujhu Care Ltd) Crs
Kampala, Uganda
- Spilhaus Crs
Harare, Zimbabwe
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 May 2026
- Primary completion
- 15 May 2028
- Completion
- 15 May 2028
- Last update posted
- 19 Feb 2026
- Registered enrollment
- 300
- Registry id
- NCT07288190
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.